ACTG repurposes osteoporosis drug alendronate in 30-person trial targeting the hidden HIV reservoir
STAIR-HIV will randomize 30 virally suppressed adults to weekly alendronate or placebo, testing whether a familiar osteoporosis medicine can perturb persistent HIV reservoirs despite continued ART.